155 related articles for article (PubMed ID: 10922227)
1. Antisense inhibition of cyclin D1 in human head and neck squamous cell carcinoma.
Nakashima T; Clayman GL
Arch Otolaryngol Head Neck Surg; 2000 Aug; 126(8):957-61. PubMed ID: 10922227
[TBL] [Abstract][Full Text] [Related]
2. Antisense cyclin D1 enhances sensitivity of head and neck cancer cells to cisplatin.
Wang MB; Yip HT; Srivatsan ES
Laryngoscope; 2001 Jun; 111(6):982-8. PubMed ID: 11404608
[TBL] [Abstract][Full Text] [Related]
3. The effect of cyclin D1 overexpression in human head and neck cancer cells.
Nakashima T; Kuratomi Y; Yasumatsu R; Masuda M; Koike K; Umezaki T; Clayman GL; Nakagawa T; Komune S
Eur Arch Otorhinolaryngol; 2005 May; 262(5):379-83. PubMed ID: 15368064
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of cyclin D1 correlates with sensitivity to cisplatin in squamous cell carcinoma cell lines of the head and neck.
Akervall J; Kurnit DM; Adams M; Zhu S; Fisher SG; Bradford CR; Carey TE
Acta Otolaryngol; 2004 Sep; 124(7):851-7. PubMed ID: 15484403
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cyclin D1 by shRNA is associated with enhanced sensitivity to conventional therapies for head and neck squamous cell carcinoma.
Kothari V; Mulherkar R
Anticancer Res; 2012 Jan; 32(1):121-8. PubMed ID: 22213296
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum.
Kornmann M; Arber N; Korc M
J Clin Invest; 1998 Jan; 101(2):344-52. PubMed ID: 9435306
[TBL] [Abstract][Full Text] [Related]
7. Third place--Resident Research Competition, AAO-2000. Antisense cyclin D1 inhibits growth of head and neck cancer xenografts in nude mice.
Wang SJ; Mintz LE; Natarajan V; Lee NJ; Srivatsan ES; Wang MB
Otolaryngol Head Neck Surg; 2001 Jun; 124(6):656-62. PubMed ID: 11391257
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of Cisplatin sensitivity in squamous cell carcinoma of the head and neck transfected with a survivin antisense gene.
Kojima H; Iida M; Yaguchi Y; Suzuki R; Hayashi N; Moriyama H; Manome Y
Arch Otolaryngol Head Neck Surg; 2006 Jun; 132(6):682-5. PubMed ID: 16785416
[TBL] [Abstract][Full Text] [Related]
9. Cyclin D1 overexpression versus response to induction chemotherapy in squamous cell carcinoma of the head and neck--preliminary report.
Akervall J; Brun E; Dictor M; Wennerberg J
Acta Oncol; 2001; 40(4):505-11. PubMed ID: 11504311
[TBL] [Abstract][Full Text] [Related]
10. Prolonged response to antisense cyclin D1 in a human squamous cancer xenograft model.
Sauter ER; Herlyn M; Liu SC; Litwin S; Ridge JA
Clin Cancer Res; 2000 Feb; 6(2):654-60. PubMed ID: 10690551
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck.
Michalides RJ; van Veelen NM; Kristel PM; Hart AA; Loftus BM; Hilgers FJ; Balm AJ
Arch Otolaryngol Head Neck Surg; 1997 May; 123(5):497-502. PubMed ID: 9158396
[TBL] [Abstract][Full Text] [Related]
12. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines.
Kalish LH; Kwong RA; Cole IE; Gallagher RM; Sutherland RL; Musgrove EA
Clin Cancer Res; 2004 Nov; 10(22):7764-74. PubMed ID: 15570011
[TBL] [Abstract][Full Text] [Related]
13. p53 mutation and cyclin D1 amplification correlate with cisplatin sensitivity in xenografted human squamous cell carcinomas from head and neck.
Henriksson E; Baldetorp B; Borg A; Kjellen E; Akervall J; Wennerberg J; Wahlberg P
Acta Oncol; 2006; 45(3):300-5. PubMed ID: 16644573
[TBL] [Abstract][Full Text] [Related]
14. Growth inhibition of head and neck squamous cell carcinoma cells by sgRNA targeting the cyclin D1 mRNA based on TRUE gene silencing.
Iizuka S; Oridate N; Nashimoto M; Fukuda S; Tamura M
PLoS One; 2014; 9(12):e114121. PubMed ID: 25437003
[TBL] [Abstract][Full Text] [Related]
15. Targeting acid ceramidase sensitises head and neck cancer to cisplatin.
Roh JL; Park JY; Kim EH; Jang HJ
Eur J Cancer; 2016 Jan; 52():163-72. PubMed ID: 26687835
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cell proliferation in head and neck squamous cell carcinoma cell lines with antisense cyclin D1.
Wang MB; Billings KR; Venkatesan N; Hall FL; Srivatsan ES
Otolaryngol Head Neck Surg; 1998 Dec; 119(6):593-9. PubMed ID: 9852531
[TBL] [Abstract][Full Text] [Related]
17. [Effects of antisense cyclin D1 expressing vector on the cell growth and apoptosis of pancreatic carcinoma].
Xu Y; Liu T; Gao J
Zhonghua Bing Li Xue Za Zhi; 1998 Oct; 27(5):348-51. PubMed ID: 11245009
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin-induced growth arrest of head and neck cancer cells correlates with increased expression of p16 and p53.
Yip HT; Chopra R; Chakrabarti R; Veena MS; Ramamurthy B; Srivatsan ES; Wang MB
Arch Otolaryngol Head Neck Surg; 2006 Mar; 132(3):317-26. PubMed ID: 16549753
[TBL] [Abstract][Full Text] [Related]
19. Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis.
Andrews GA; Xi S; Pomerantz RG; Lin CJ; Gooding WE; Wentzel AL; Wu L; Sidransky D; Grandis JR
Head Neck; 2004 Oct; 26(10):870-7. PubMed ID: 15390206
[TBL] [Abstract][Full Text] [Related]
20. Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line.
Hochhauser D; Schnieders B; Ercikan-Abali E; Gorlick R; Muise-Helmericks R; Li WW; Fan J; Banerjee D; Bertino JR
J Natl Cancer Inst; 1996 Sep; 88(18):1269-75. PubMed ID: 8797766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
